Search Results

You are looking at 1 - 2 of 2 items for :

Clear All
Open access

Maria-Magdalena Leon-Constantin, Alexandra Maștaleru, Ovidiu Mitu, Madalina Zota, Teodor Vasilcu, Radu Gavril and Florin Mitu

, Lopes RD, James S et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl JMed. 2011;365(8):699-708. 8. Korjian S, Braunwald E, Daaboul Y et al. Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarkerpositive patients: Insights from the ATLAS ACS 2-TIMI 51 trial. Eur Heart J Acute Cardiovasc Care. 2017:2048872617745003. 9. Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-91. 10

Open access

Pașc Priscilla, Ioana Alexandra Coţe and Mircea Ioachim Popescu

in the elderly after acute coronary syndromes. The Myocardial Ischaemia National Audit Project 2003–2010. Eur Heart J. 2012;33(5):630–9. 10.1093/eurheartj/ehr381 7. De Carlo M, Morici N, Savonitto S, et al. : Sex-Related Outcomes in Elderly Patients Presenting With Non-STSegment Elevation Acute Coronary Syndrome: Insights From the Italian Elderly ACS Study. JACC Cardiovasc Interv. 2015;8(6):791–6. 10.1016/j.jcin.2014.12. 8. Tegn N, Abdelnoor M, Aaberge L, et al. : Invasive versus conservative strategy in patients aged 80 years or older with non